Clinical Trial Update: MemoryXL Effects on Mild Cognitive Impairment Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial of MemoryXL in mild cognitive impairment was terminated, and results were posted in January 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• MemoryXL

Snippet

Sponsor: University of Oklahoma | Conditions: Mild Cognitive Impairment | Phase 2 | Status: TERMINATED | Results posted: 2012-01-26